U.S. markets closed
  • S&P 500

    4,455.48
    +6.50 (+0.15%)
     
  • Dow 30

    34,798.00
    +33.18 (+0.10%)
     
  • Nasdaq

    15,047.70
    -4.54 (-0.03%)
     
  • Russell 2000

    2,248.07
    -10.97 (-0.49%)
     
  • Crude Oil

    73.95
    +0.65 (+0.89%)
     
  • Gold

    1,750.60
    +0.80 (+0.05%)
     
  • Silver

    22.42
    -0.26 (-1.16%)
     
  • EUR/USD

    1.1718
    -0.0029 (-0.25%)
     
  • 10-Yr Bond

    1.4600
    +0.0500 (+3.55%)
     
  • GBP/USD

    1.3681
    -0.0040 (-0.29%)
     
  • USD/JPY

    110.6850
    +0.3840 (+0.35%)
     
  • BTC-USD

    42,219.34
    -340.61 (-0.80%)
     
  • CMC Crypto 200

    1,067.20
    -35.86 (-3.25%)
     
  • FTSE 100

    7,051.48
    -26.87 (-0.38%)
     
  • Nikkei 225

    30,248.81
    +609.41 (+2.06%)
     

Cyclerion Recruits Beacon Biosignals To Identify Disease-Relevant EEG Neurological Biomarkers

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Cyclerion Therapeutics Inc (NASDAQ: CYCN) and Beacon Biosignals have expanded strategic partnerships between the two companies.

  • This collaboration is expected to identify disease-relevant biomarkers to refine patient selection and endpoints to guide Cyclerion's CY6463 and CY3018 programs for neurological diseases associated with cognitive impairment.

  • Beacon Biosignals' electroencephalogram (EEG) neurobiomarker platform is engineered to discover and scale new clinical paradigms for neurological and psychiatric diseases.

  • The companies previously collaborated on analyzing data from a Cyclerion clinical translational pharmacology study of CY6463.

  • CY6463 lead candidate is an oral central nervous system (CNS)-penetrant sGC stimulator.

  • Initial data from CY6463 trials have demonstrated favorable safety and tolerability and pharmacologically relevant drug exposure in the cerebral spinal fluid.

  • In addition, CY6463 resulted in promising impacts on EEG measures, neuroinflammation, and other neurophysiological measures that support continued clinical development.

  • Further evaluation of CY6463 in Alzheimer's disease with vascular pathology and Mitochondrial Encephalomyopathy, Lactic Acidosis, and Stroke-like episodes are ongoing.

  • A study in Cognitive Impairment Associated with Schizophrenia is expected to initiate shortly.

  • Price Action: CYCN shares closed at $3.68 on Thursday.

See more from Benzinga

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.